Hunan Erkang Pharmaceutical's controlling shareholder Shuai Fangwen plans to reduce holdings by no more than 42 million shares, accounting for 2.04% of the total share capital.

MaticHoleFiller · 2026-04-10T04:39:42+00:00

Eerkang Pharmaceutical's controlling shareholder Shuai Fangwen plans to reduce holdings by no more than 42 million shares, accounting for 2.04% of the total share capital, within the next three months. The reason for the reduction is funding needs. After the reduction, they will still be the controlling shareholder, and it is not expected to affect the company's control or ongoing operations. However, the reduction may have an uncertain impact on the stock price, and investors should exercise caution.

MaticHoleFiller

2026-04-10 04:39:42

Abstract generation in progress

Hunan Erkang Pharmaceutical Co., Ltd. (hereinafter referred to as “Erkang Pharmaceutical”) announced on March 31, 2026, that the company’s controlling shareholder, Shuai Fangwen, plans to reduce his holdings in the company within the next three months, intending to sell no more than 42 million shares, accounting for 2.04% of the company’s total share capital.

Core Content of the Reduction Plan

The announcement shows that Shuai Fangwen currently holds 853,574,906 shares of Erkang Pharmaceutical, accounting for 41.38% of the company’s total share capital, making him the controlling shareholder. The main details of this reduction plan are as follows:

Item
Specific Content
—
Reason for Reduction
Shareholder’s own funding needs
Source of Shares
Shares issued before the company’s initial public offering and shares from rights issues and bonus shares
Reduction Period
Within three months after 15 trading days from the date of this announcement, i.e., from April 23, 2026, to July 22, 2026
Reduction Method
Centralized bidding transactions or block trades
Proposed Reduction Quantity
No more than 42M shares (42 million shares)
Proposed Reduction Ratio
No more than 2.04% of the company’s total share capital
Price Range
Determined by market price, not lower than the issuance price at the time of the initial public offering (adjusted accordingly after dividends and rights issues)
Reduction Restrictions
Within any consecutive ninety calendar days, reduction via centralized bidding shall not exceed 1% of the total share capital, and reduction via block trades shall not exceed 2% of the total share capital

Risk Warning and Impact Analysis

Erkang Pharmaceutical reminds in the announcement that there is uncertainty regarding the implementation of this reduction plan. Shuai Fangwen will decide on the specific implementation based on market conditions, the company’s stock price, and other factors. The timing, quantity, and price of the reduction are all uncertain.

The announcement also emphasizes that after this reduction plan is implemented, Shuai Fangwen will still be the company’s controlling shareholder, and it will not lead to a change in the company’s control rights, nor will it affect the company’s ongoing operations. The company’s board of directors will supervise relevant shareholders to strictly comply with laws and regulations and fulfill information disclosure obligations in a timely manner.

It is understood that Shuai Fangwen’s reduction does not violate the “Interim Measures for the Management of Shareholder Reductions in Listed Companies,” “Guidelines for Self-Regulation of Listed Companies on the Shenzhen Stock Exchange No. 18—Shareholder and Director, Senior Management Shareholding Reductions,” or other relevant regulations, nor has there been any breach of commitments.

Investors should note that shareholder reductions may have a certain impact on the company’s stock price. It is recommended to invest rationally and pay attention to subsequent related announcements.

Disclaimer: The market carries risks; investment should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. All information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for any discrepancies. If you have questions, please contact biz@staff.sina.com.cn.

Click to view the original announcement>>

Massive information, precise interpretation, all on Sina Finance APP

Editor: Xiao Lang Express

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes